Trials / Completed
CompletedNCT04622345
Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies
A Single-Center, Double-Masked, Randomized, Placebo-Controlled, Phase 2, Evaluation of the Safety and Efficacy of VSJ-110 Ophthalmic Solution in the Treatment of Allergic Conjunctivitis Using an Allergen Challenge Model
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Vanda Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of allergic conjunctivitis using an antigen challenge model
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VSJ-110 | ophthalmic solution |
| DRUG | Placebo | ophthalmic solution |
Timeline
- Start date
- 2020-11-21
- Primary completion
- 2021-05-22
- Completion
- 2021-06-28
- First posted
- 2020-11-09
- Last updated
- 2025-09-11
- Results posted
- 2025-09-11
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04622345. Inclusion in this directory is not an endorsement.